Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
MEN1
REST API REST API
Homo sapiens
MEN1 is differentially expressed in 223 experiments: 78 organism parts: liver, blood, ... (76 more);, 147 disease states: normal, control, ... (145 more);, 67 cell types 255 cell lines 25 compound treatments and 55 other conditions.
Orthologs Men1 (Rattus norvegicus)   men1 (Danio rerio)   ENSCING00000001396 (Ciona intestinalis)   Men1 (Mus musculus)   MEN1_BOVIN (Bos taurus)   MEN1 (2 of 2) (Danio rerio)   Mnn1 (Drosophila melanogaster)   men1 (Xenopus laevis)   A2SXS5_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term response to UV, cytosol, positive regulation of cell division, embryo development, DNA binding, positive regulation of caspase activity, negative regulation of transcription, DNA-dependent, protein binding, cleavage furrow, DNA repair, cytoplasm, double-stranded DNA binding, negative regulation of cell proliferation, protein complex, histone methylation, protein N-terminus binding, MAPKKK cascade, cell cycle arrest, nuclear matrix, positive regulation of transforming growth factor beta receptor signaling pathway, positive regulation of apoptosis, negative regulation of organ growth, soluble fraction, hemopoiesis, positive regulation of transcription from RNA polymerase II promoter, Y-form DNA binding, nucleus, negative regulation of JNK cascade, chromatin remodeling, chromatin binding, four-way junction DNA binding, chromatin, protein binding, bridging, negative regulation of transcription from RNA polymerase II promoter, response to DNA damage stimulus, response to gamma radiation, brain development, negative regulation of cell cycle, positive regulation of transcription, DNA-dependent, negative regulation of cyclin-dependent protein kinase activity, histone methyltransferase complex, histone-lysine N-methyltransferase activity, osteoblast fate commitment, negative regulation of osteoblast differentiation, negative regulation of telomerase activity, positive regulation of histone methylation, embryonic skeletal system morphogenesis, ossification, osteoblast development, positive regulation of cell differentiation, leukocyte homeostasis, histone lysine methylation, maternal process involved in female pregnancy, regulation of activin receptor signaling pathway, positive regulation of osteoblast differentiation, palate development, R-SMAD binding, positive regulation of protein binding, negative regulation of protein phosphorylation, negative regulation of sequence-specific DNA binding transcription factor activity, transcription regulatory region DNA binding
InterPro Term Menin
UniProt Accession C9DZM4, Q9GZQ5, O00255, E7EN32, E7ENS2, E7EPR4, E7ET29
Gene-Disease Assocation MULTIPLE ENDOCRINE NEOPLASIA, TYPE I; MEN1, HYPERPARATHYROIDISM 1; HRPT1
Search EB-eye ENSG00000133895
Show more properties
Experimental Factors
Organism part

studied in E-AFMX-5, E-GEOD-6573, E-MTAB-24, E-MTAB-25, E-GEOD-6919, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (35 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MEXP-440, E-MTAB-62
MCF-7
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
Jurkat
2
E-MEXP-2197, E-GEOD-1880
MDAMB175VII
2
E-MTAB-37, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
GM10843
1
E-TABM-321
249 more value(s).


Cell type

studied in E-GEOD-3920, E-GEOD-20677, E-GEOD-4219, E-GEOD-13987, E-TABM-34, ... (34 experiments)

Factor Value U/D Experiments
CD71+ early erythroid
2
E-AFMX-5, E-TABM-145
CD105+ endothelial
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-3204
not specified
2
E-GEOD-18811, E-GEOD-11755
CD34+ cell
1
E-MEXP-583
pro B cell
1
E-MEXP-1403
61 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MTAB-62, E-GEOD-5370, ... (54 experiments)

Factor Value U/D Experiments
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-GEOD-96
lung adenocarcinoma
3
E-MEXP-231, E-MTAB-37, E-MTAB-62
lymphoma
2
E-MTAB-37, E-MTAB-62
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
acute quadriplegic myopathy
2
E-MTAB-62, E-GEOD-3307
141 more value(s).


Compound treatment

studied in E-GEOD-6907, E-TABM-782, E-GEOD-5824, E-GEOD-3720, E-TABM-868, ... (17 experiments)

Factor Value U/D Experiments
none
2
5
E-GEOD-5824, E-GEOD-412, E-TABM-782, E-GEOD-2649, E-GEOD-995, ... (7 experiments)
no estradiol
1
E-GEOD-20081
phoshate buffered saline
1
E-GEOD-3720
unknown
1
E-GEOD-7307
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
17beta-estradiol
4
1
E-GEOD-2292
19 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cellular component
studied in E-GEOD-1400

Classifier
studied in E-GEOD-3493

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, E-GEOD-512, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-21374, E-GEOD-4619, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-5377, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, E-GEOD-2666, ... (6 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-22148, E-TABM-147, E-GEOD-21138, ... (6 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578

Genotype
studied in E-TABM-1029, E-GEOD-2466, E-GEOD-22593, E-GEOD-2292, E-TABM-868, ... (7 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-20504, E-MEXP-1446, E-GEOD-22278, ... (9 experiments)

Histology
studied in E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-TABM-666, E-GEOD-6919, ... (24 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-9723, E-GEOD-980 ... (5 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Labeling
studied in E-LGCL-5

Material type
studied in E-MEXP-455, E-MEXP-958

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-19703, E-GEOD-21750, E-MEXP-1403

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Test result
studied in E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-19815

Tumor grading
studied in E-GEOD-4290, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.395 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM